Severe respiratory adverse events associated with rituximab infusion.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

1. Rituximab for refractory cases of childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011
   Trial
2. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2020
   Review
3. Drug-Free Macromolecular Therapeutics Induce Apoptosis via Calcium Influx and Mitochondrial Signaling Pathway.Macromolecular bioscience · 2018
   Article
4. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.ACS nano · 2014
   Article
5. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Oncoimmunology · 2013
   Review
6. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2013
   Article
7. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2013
   Article
8. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis.Biomaterials · 2012
   Article
9. Should we consider MMF therapy after rituximab for nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 2011
   Article
10. New therapies, new concerns: rituximab-associated lung injury.Pediatric nephrology (Berlin, Germany) · 2010
    Review
11. Rituximab Treatment for Nephrotic Syndrome in Children.Current pediatrics reports
    Article

Corrections and comments

• Comment on
  Fatal pulmonary fibrosis after rituximab administration.2009

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as